Chronic Low Back Pain (LBP) is among the most common medical conditions.

Approximately 70-80% of people experience symptoms at least once in their lifetime, and approximately one quarter of adults in the US report experiencing LBP in the past 3 months. Such statistics show the clear need to improve quality of life for people with LBP through treatments that adhere to clinical guidelines, which recommend first-line treatments of exercise, time and non-invasive therapies like physical therapy and chiropractic care, and discourage the use of opioids and unnecessary complex surgeries.

As the prevalence of Low Back Pain is enormous, its impact on the health system and economics is a significant challenge, as projected by the fact that it is the most influencing work-related disability in the US.

Recent research conducted by OptumLabs and Boston University School of Public Health provides insight into opportunities for better care options:

The research finds that a patient’s initial choice in health care provider (i.e.,seeing a non-invasive therapist first, vs. a primary care physician [PCP]) for a new episode of LBP, results in much lower odds of early and long-term opioid use.

In recent years, opioid prescription for low back pain has increased, and in the US, opioids are the most prescribed drug class 2 . More than half of regular opioid users report back pain. Complications of opioid use include addiction and overdose related mortality, which have risen in parallel with prescription rates, leading to the opioid crisis: 46 people per day, or almost 17,000 people per year, die from overdoses of chronic pain killing opioid drugs.

Other study published at the Journal of the American Medical Association found that too many complex back surgeries are being done and patients are suffering as a result from complications. The study also show that most back surgeries make a minimal difference.

The findings also suggest that health plans could play an important role in making it easier for consumers to consider non-invasive therapies for LBP.

The market needs are summarized

• Prevalence of the problem – (1 in 4)
• Dependability on professional treatment, high treatment volumeand maintenance (physical medicine, drugs and/or surgeries)
• Chasing mainly after recurrent symptoms, disregarding asolution for the functional root cause of the problem andprevention.
• High Individual (1000+$ per case) & global (USA -> 135billion annually) expenditures.
• High Potential risk of invasive procedures and opioid drugs
• LBP conditions are degenerative & progressive processes (20-30 years)
• Relative long Duration in disability and pain (a few weeks)

Our innovative advantages

• L-PACT automated device may significantly scale up treatmentcapacity and efficiency for clinicians and clinics. It increasespatient's engagement, follow-up and retention rate, improvesevidence-based results and uniformity of assesment forcomparison
• L-PACT may serve as the first line treatment of choice for self, orguided treatment of LBP (wearable-fully automatedindividualized, accessible, easy to follow, short treatment)
• L-PACT targets the functional root cause of LBP and is notintended for symptomatic relief only but for prevention.

There is an unmet need for a non-invasive, safe, and automated device that will provide fast, efficient, and individualized assessment and treatment for the mechanical underlying cause of low back pain.
Our solution offers a self-regulated advantage, addressing long term treatment goals and prevents degenerative processes and deterioration.